Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

Prostate Cancer Clinical Trial

Official title:

Prospective Single-Center Randomized Study Of Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound (HIFU)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05610852
• Other study ID #: CASE10822
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 1, 2024
• Est. completion date: July 1, 2028

Study information

• Verified date: May 2024
• Source: Case Comprehensive Cancer Center
• Contact: Jihad Kaouk, MD
• Phone: 216-444-2976
• Email: kaoukj[@]ccf.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.

Description:

The primary objective is to evaluate the in-field recurrence rates and recurrence free survival - defined as the absence of clinically significant prostate cancer within the treated zone (identified by prostate MRI and subsequent targeted prostate biopsy). Secondary objectives of interest are: - Perioperative parameters such as operative time, perioperative complications, analgesic requirement, postoperative hospital stay, foley catheter duration - Functional outcomes such as time to urinary continence, urinary continence, and erectile dysfunction - Oncologic outcomes such as biochemical recurrence rates (defined in section 2.1), recurrence free survival, presence of secondary intervention for prostate cancer (HIFU, radiation, surgery, ADT)

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 276
• Est. completion date: July 1, 2028
• Est. primary completion date: July 1, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Subjects must have histologically or cytologically: Biopsy-confirmed prostate cancer, stage T1a, T2a, T2b, or T2c prostate cancer using MRI staging, with a region of interest (ROI) PIRADs grade 3 or greater, Serum PSA 10 ng/ml or less, Region of interest on MRI of grade 3 or greater
• The MRI performed must include at least:
• A T2-weighted sequence in sections = 4 mm, centered on the prostate and seminal vesicles, at least in the axial plane. Alternatively, a 3D T2-weighted sequence can be realized,
• A diffusion sequence of = 4 mm slice in the axial plane. An ADC card will be provided and calculated from at least two values of b, the maximum value of b being = 600 s / mm2,
• A dynamic sequence after gadolinium injection. It will be a sequence of echo T1-weighted gradient of slice = 4 mm, centered on the prostate and seminal vesicles in the axial plane, with or without fat saturation. A first series will be performed without contrast injection, and will be repeated iteratively for the arrival of a bolus of gadolinium chelates. The time resolution (that is to say, the acquisition time of one dynamic series will be = 20 seconds). The number of chained dynamic series is calculated so that the total length of the dynamic acquisition be at least 3 minutes
• A total dose of 0.1 mmol / kg of gadolinium chelate will be injected at a rate of 3-4 mL / s by using an automatic injector, in a vein of the hand of the forearm or elbow.
• If necessary, subtracted images are calculated
• Clinically significant prostate cancer defined as Gleason score 3+4 or less in any core
• Biopsies for preoperative diagnosis of prostate cancer will have included: At least 12 randomized samples (2 samples per sextant), At least two targeted sampling on each target score MRI ESUR = 3/5
• Life expectancy greater than 10 years.
• Age >18 years.
• Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients with any prior extensive pelvic surgery, pelvic fractures, hemorrhoid, fissure surgery, cardiac pacemaker, or metal prosthesis
• Prior treatment for prostate cancer such as radiotherapy, focal or hormonal therapy
• Uncorrected coagulopathy or history of Latex allergy
• Active soft tissue or urinary infection, indwelling Foley catheter or severe irritative or obstructive symptoms
• Poor surgical risk (defined as American Society of Anesthesiology score > 3).
• Any condition or history of illness or surgery that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient (e.g. significant cardiovascular conditions that significantly affect the life expectancy, chronic opiate use, pain syndrome, or drug abuse.)
• Prostate size larger than 80 grams.
• Subjects with prostatic Calcification (>0.5 cc) close to the area to be treated.
• Subjects with extraprostatic extension or cribriform pattern on biopsy.
• Subjectes with sexual dysfunction defined as SHIM score < 17
• Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Related Conditions & MeSH terms

• Adenocarcinoma
• Prostate Adenocarcinoma
• Prostate Cancer

Intervention

Procedure:
• Transvesical Single Port Robotic Partial Prostatectomy
A foley catheter is inserted on the sterile field. A suprapubic midline incision is made and the da Vinci SP surgical system is docked percutaneously directly to the bladder. Prior to the operation, a radiologist identifies and segments tumors and the urethra. A transrectal ultrasound probe is inserted and secured into a fixed position. The Koelis software is utilized to fuse MRI and ultrasound images to identify the target lesion in real-time, allowing for intraoperative guidance. The ultrasound probe rotates automatically, allowing for localization of the tumor intraoperatively. Then depending on the area of the tumor, a Hemi or quadrant resection is completed while preserving the nerves, vas deferens, and seminal vesicles. The urethrovesical anastomosis is then performed.
• High-intensity focused ultrasound (HIFU)
Three contoured measurements are required for the MR fusion system to reproduce the volume of the prostate. Following this, the area to be targeted will be selected in graded fashion from the anterior to posterior of the prostate. Once planning of ROI (region of interest) is complete, the HIFU treatment may begin. Quadrant or hemi ablation will be performed based on the size and complexity of the tumor. The distal margin of the ablation will be kept at least 4 mm away from the external sphincter. The rectal temperature and its distance from the probe will be carefully monitored throughout the procedure.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Case Comprehensive Cancer Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence free survival Recurrence free survival	Number of patients with absence of clinically significant prostate cancer on prostate MRI and targeted prostate biopsy	1 year after treatment
Primary	Recurrence free survival	Number of patients with absence of clinically significant prostate cancer on prostate MRI and targeted prostate biopsy	2 years after treatment
Primary	Recurrence free survival	Number of patients with absence of clinically significant prostate cancer on prostate MRI and targeted prostate biopsy	3 years after treatment
Secondary	Operative time	Minutes from incision to closing during surgery (median)	At initial treatment (postoperative day 0)
Secondary	Postoperative Complications	Clavien-dindo classification number (1-5), number (percent)	Within 3 months after treatment.
Secondary	Analgesic requirment	Units of oral morphine equivalent dosing (mg), median	Once at first follow up (up to 7 days after initial treatment)
Secondary	Postoperative hospital stay	Time that patient is observed in the hospital after surgery, in hours (median)	Up to 1 day after initial treatment
Secondary	Foley catheter duration	Time at which the foley catheter is removed after treatment, in days (median)	Up to 7 days after initial treatment
Secondary	Time to urinary continence	Time at which the patient becomes continent in days (median)	Assessed at each visit for up to 1 year after treatment
Secondary	Urinary continence	Continence defined as using 1 pad for security or less for stress urinary incontince, recorded as yes or no (percent)	Assessed at each visit for up to 1 year after treatment
Secondary	Erectile dysfunction	Assessed using scores from a validated survey (IIEF-5). Recorded as the the score from 5 (impotent) to 25 (no impotence), median.	Assessed at each visit for up to 3 years
Secondary	Biochemical recurrence	PSA recurrence defined as PSA nadir after treatment +1ng/ml within 12 months or PSA Nadir + 1.5ng/ml from 12-36 months. Recorded as yes or no (percent)	Assessed at each visit for up to 3 years
Secondary	Secondary interventions	Time point at which the patient undergoes treatment for prostate cancer recurrence	Assessed at the time of clinic visits up to 3 years after treatment.